Welcome to our dedicated page for Zenas BioPharma news (Ticker: ZBIO), a resource for investors and traders seeking the latest updates and insights on Zenas BioPharma stock.
Zenas BioPharma, Inc. (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company focused on autoimmune diseases, and its news flow reflects active development across multiple programs. Company announcements frequently highlight progress with its lead product candidate, obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb across the B cell lineage to inhibit cells implicated in autoimmune disease without depleting them. News items include updates on the Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease (IgG4-RD), Phase 2 MoonStone trial in Relapsing Multiple Sclerosis (RMS), and Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE), including reports of statistically significant efficacy results and safety findings.
Investors following ZBIO news can also track developments related to orelabrutinib, a late-stage, highly selective CNS-penetrant, oral BTK inhibitor licensed from InnoCare Pharma. Press releases cover Phase 3 trials in Primary Progressive Multiple Sclerosis (PPMS) and planned trials in Secondary Progressive Multiple Sclerosis (SPMS), as well as partner-reported data in SLE. Additional news covers earlier-stage programs ZB021 and ZB022, described as potentially best-in-class oral IL-17AA/AF and TYK2 inhibitors in IND-enabling or preclinical stages.
Regulatory, financing and corporate updates are another key component of Zenas BioPharma’s news. The company issues releases on revenue participation and funding agreements, such as its obexelimab funding arrangement with Royalty Pharma, private placement financings, and material license agreements with InnoCare. Earnings-related press releases and Form 8-K–linked announcements provide context on cash runway, research and development spending, and strategic priorities.
This ZBIO news page aggregates these disclosures so readers can follow clinical milestones, regulatory plans, licensing transactions and capital raises associated with Zenas’ autoimmune pipeline. For investors, analysts and healthcare professionals, it offers a single view into how obexelimab, orelabrutinib, ZB021 and ZB022 are progressing through development and how the company is structuring partnerships and funding to support its programs.
Zenas BioPharma (Nasdaq: ZBIO) announced its 2024 achievements and 2025 objectives, highlighting progress in clinical trials for obexelimab, their key autoimmune disease therapy. The company enters 2025 with approximately $350 million in cash, expected to fund operations into Q4 2026.
Key 2024 accomplishments include completing enrollment for the Phase 3 INDIGO trial for IgG4-Related Disease, initiating Phase 2 trials for Multiple Sclerosis (MoonStone) and Systemic Lupus Erythematosus (SunStone), and raising $458.7 million through Series C and IPO funding. The company also out-licensed its thyroid eye disease programs to Zai Lab for Greater China.
For 2025, Zenas anticipates reporting topline results from the MoonStone trial in Q3 2025, Phase 3 INDIGO trial results by year-end 2025, and completing enrollment for the SunStone trial with results expected in H1 2026.
Zenas BioPharma (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company focused on immunology-based therapies, has announced its participation in the Guggenheim SMID Cap Biotech Conference. The company's management will engage in a fireside chat presentation scheduled for Wednesday, February 5, 2025, at 3:00 p.m. ET.
Interested parties can access both the live webcast and archived replay of the presentation through the 'Events and Presentations' section within the Investor & Media Relations area of the Zenas BioPharma website.
Zenas BioPharma (ZBIO) completed its IPO, raising $258.7 million in gross proceeds, and reported Q3 2024 financial results. The company completed targeted enrollment for its Phase 3 INDIGO trial of obexelimab for IgG4-RD treatment, with topline results expected by end of 2025. R&D expenses increased to $33.5 million from $9.4 million year-over-year, while G&A expenses rose to $7.5 million from $5.0 million. The company reported a net loss of $38.6 million. Cash balance stands at $386.8 million, expected to fund operations into Q4 2026.
Zenas BioPharma (NASDAQ: ZBIO) has completed targeted enrollment for its Phase 3 INDIGO trial of obexelimab, a treatment for IgG4-Related Disease (IgG4-RD). The INDIGO trial represents the largest clinical trial ever conducted for IgG4-RD patients. The company expects to report topline results by the end of 2025. This milestone demonstrates Zenas's ability to execute its clinical development plans as it works toward becoming a leader in immunology-based therapies.
Zenas BioPharma (Nasdaq: ZBIO), a clinical-stage biopharmaceutical company, has announced its participation in four major healthcare investor conferences in November and December 2024. The company will present at the Guggenheim's Inaugural Healthcare Innovation Conference in Boston, Jefferies London Healthcare Conference, Citi's Global Healthcare Conference in Miami, and Evercore ISI HealthCONx Conference in Coral Gables. Live webcasts and archived replays of presentations at Jefferies, Citi, and Evercore conferences will be available on the company's website under the Investors and Media section.
Zenas BioPharma (Nasdaq: ZBIO), a clinical-stage biopharmaceutical company, announced the closing of the underwriters' full exercise of their option to purchase an additional 1,985,294 shares at $17.00 per share in its upsized initial public offering (IPO). This follows the initial offering of 13,235,294 shares, which closed on September 16, 2024. The total offering now amounts to 15,220,588 shares, generating gross proceeds of approximately $258.7 million. The shares began trading on the Nasdaq Global Select Market on September 13, 2024. Morgan Stanley, Jefferies, Citigroup, and Guggenheim Securities served as joint book-running managers. Registration statements for the shares were filed with the U.S. Securities and Exchange Commission and became effective on September 12, 2024.
Zenas BioPharma (Nasdaq: ZBIO) has announced the pricing of its upsized initial public offering (IPO) of 13,235,294 shares at $17.00 per share. The company expects to raise approximately $225.0 million in gross proceeds. Trading on the Nasdaq Global Select Market is set to begin on September 13, 2024, with the offering closing on September 16, 2024. Zenas has granted underwriters a 30-day option to purchase up to an additional 1,985,294 shares at the IPO price. Morgan Stanley, Jefferies, Citigroup, and Guggenheim Securities are acting as joint book-running managers for the offering.